These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

311 related articles for article (PubMed ID: 23727412)

  • 21. A systematic review and meta-analysis on the use of phosphodiesterase 5 inhibitors alone or in combination with α-blockers for lower urinary tract symptoms due to benign prostatic hyperplasia.
    Gacci M; Corona G; Salvi M; Vignozzi L; McVary KT; Kaplan SA; Roehrborn CG; Serni S; Mirone V; Carini M; Maggi M
    Eur Urol; 2012 May; 61(5):994-1003. PubMed ID: 22405510
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Role of Antimuscarinics Combined With Alpha-blockers in the Management of Urinary Storage Symptoms in Patients With Benign Prostatic Hyperplasia: An Updated Systematic Review and Meta-analysis.
    Lenfant L; Pinar U; Roupret M; Mozer P; Chartier-Kastler E; Seisen T
    J Urol; 2023 Feb; 209(2):314-324. PubMed ID: 36395428
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A prospective, randomized, open-label, parallel trial comparing the efficacy of α-blocker or 5α-reductase inhibitor withdrawal to continued combination therapy on the maintenance of lower urinary tract symptoms in men with benign prostatic hyperplasia.
    Lee KS; Yoo JW; Kim DH; Jeon S; Yang J; Chung BH; Koo KC
    Prostate; 2024 Mar; 84(4):403-413. PubMed ID: 38149792
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Desmopressin add-on therapy for refractory nocturia in men receiving α-blockers for lower urinary tract symptoms.
    Bae WJ; Bae JH; Kim SW; Chung BH; Kim JH; Kim CS; Lee HM; Lee KS; Yoo TK; Kim SI; Byun SS; Lee JY
    J Urol; 2013 Jul; 190(1):180-6. PubMed ID: 23357213
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [The results of the multicenter prospective comparative study of Androgel in men with endogenous testosterone deficiency and lower urinary tract symptoms, associated with benign prostate hyperplasia (POTOK)].
    Kogan MI; Avadieva NE; Gevorkyan LS; Loginov YA; Metelkin AM; Mitin AA; Patrikeev AA
    Urologiia; 2023 May; (2):32-40. PubMed ID: 37401702
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Long-term risk of benign prostatic hyperplasia-related surgery and acute urinary retention in men treated with 5-alpha reductase inhibitor versus alpha-blocker monotherapy in routine clinical care.
    Bengtsen MB; Heide-Jørgensen U; Borre M; Nørgaard M
    Prostate; 2023 Jul; 83(10):980-989. PubMed ID: 37057816
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A multicenter real-life study of the efficacy of an alpha-blocker with or without anticholinergic agent (imidafenacin) treatment in patients with lower urinary tract symptoms/benign prostatic hyperplasia and storage symptoms.
    Cho S; Kwon SS; Lee KW; Yoo TK; Shin DG; Kim SW; Bae JH; Choi H; Kim YH
    Int J Clin Pract; 2017 May; 71(5):. PubMed ID: 28508455
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Long-term safety and efficacy of single-tablet combinations of solifenacin and tamsulosin oral controlled absorption system in men with storage and voiding lower urinary tract symptoms: results from the NEPTUNE Study and NEPTUNE II open-label extension.
    Drake MJ; Chapple C; Sokol R; Oelke M; Traudtner K; Klaver M; Drogendijk T; Van Kerrebroeck P;
    Eur Urol; 2015 Feb; 67(2):262-70. PubMed ID: 25070148
    [TBL] [Abstract][Full Text] [Related]  

  • 29. BPH progression: concept and key learning from MTOPS, ALTESS, COMBAT, and ALF-ONE.
    Roehrborn CG
    BJU Int; 2008 Mar; 101 Suppl 3():17-21. PubMed ID: 18307681
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Clinical effectiveness and safety study of combined therapy with an alpha-blocker and an anticholinergic for patients with LUT/BPH].
    Xiao H; Li HZ; Yang Y; Huang ZM; Li YQ; Zhao XF
    Zhonghua Yi Xue Za Zhi; 2007 Jun; 87(23):1590-3. PubMed ID: 17803845
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Phosphodiesterase inhibitors for lower urinary tract symptoms consistent with benign prostatic hyperplasia.
    Pattanaik S; Mavuduru RS; Panda A; Mathew JL; Agarwal MM; Hwang EC; Lyon JA; Singh SK; Mandal AK
    BJU Int; 2019 Jul; 124(1):27-34. PubMed ID: 30681264
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Efficacy of Adding Dutasteride to α-Blocker Therapy Treated Benign Prostatic Hyperplasia Patients with Small Volume Prostate (<30 mL).
    Hashimoto M; Shimizu N; Sugimoto K; Hongoh S; Minami T; Nozawa M; Yoshimura K; Hirayama A; Tahara H; Uemura H
    Low Urin Tract Symptoms; 2017 Sep; 9(3):157-160. PubMed ID: 26991643
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effects of serum PSA on efficacy of tolterodine extended release with or without tamsulosin in men with LUTS, including OAB.
    Roehrborn CG; Kaplan SA; Kraus SR; Wang JT; Bavendam T; Guan Z
    Urology; 2008 Nov; 72(5):1061-7; discussion 1067. PubMed ID: 18817961
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Influence of baseline variables on changes in International Prostate Symptom Score after combined therapy with dutasteride plus tamsulosin or either monotherapy in patients with benign prostatic hyperplasia and lower urinary tract symptoms: 4-year results of the CombAT study.
    Roehrborn CG; Barkin J; Tubaro A; Emberton M; Wilson TH; Brotherton BJ; Castro R
    BJU Int; 2014 Apr; 113(4):623-35. PubMed ID: 24127818
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Does anticholinergic medication have a role in treating men with overactive bladder and benign prostatic hyperplasia?
    Lee KS; Lee HW; Han DH
    Naunyn Schmiedebergs Arch Pharmacol; 2008 Jun; 377(4-6):491-501. PubMed ID: 18172610
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Pharmacological treatment of benign prostatic hyperplasia].
    Oelke M; Kuczyk MA; Herrmann TR
    Urologe A; 2009 Nov; 48(11):1365-75; quiz 1376-7. PubMed ID: 19851747
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Comparative Effectiveness of Newer Medications for Lower Urinary Tract Symptoms Attributed to Benign Prostatic Hyperplasia: A Systematic Review and Meta-analysis.
    Dahm P; Brasure M; MacDonald R; Olson CM; Nelson VA; Fink HA; Rwabasonga B; Risk MC; Wilt TJ
    Eur Urol; 2017 Apr; 71(4):570-581. PubMed ID: 27717522
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Safety and efficacy of the combination of once-daily tadalafil and alpha-1 blocker in Japanese men with lower urinary tract symptoms suggestive of benign prostatic hyperplasia: A randomized, placebo-controlled, cross-over study.
    Takeda M; Yokoyama O; Yoshida M; Nishizawa O; Hirata K; Nakaoka R; Takita Y; Murakami M
    Int J Urol; 2017 Jul; 24(7):539-547. PubMed ID: 28556284
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A review of combination therapy in patients with benign prostatic hyperplasia.
    McVary KT
    Clin Ther; 2007 Mar; 29(3):387-98. PubMed ID: 17577460
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Efficacy and safety of PDE5-Is and α-1 blockers for treating lower ureteric stones or LUTS: a meta-analysis of RCTs.
    Sun X; Guan W; Liu H; Tang K; Yan L; Zhang Y; Zeng J; Chen Z; Xu H; Ye Z
    BMC Urol; 2018 May; 18(1):30. PubMed ID: 29724204
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.